NasdaqGM - Delayed Quote • USD
Harmony Biosciences Holdings, Inc. (HRMY)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 5:48 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jeffrey S. Aronin | Founder & Non-Executive Chairman | 185.67k | -- | 1968 |
| Dr. Jeffrey M. Dayno M.D. | President, CEO & Director | 1.26M | -- | 1957 |
| Mr. Jeffrey Dierks M.B.A. | Executive VP & Chief Commercial Officer | 830.75k | -- | 1972 |
| Mr. Andrew Serafin J.D., M.B.A. | Executive VP & Chief Strategy Officer | 647.42k | -- | 1975 |
| Dr. Kumar Budur M.D., M.S. | Executive VP & Chief Medical Officer | 760.81k | -- | -- |
| Mr. David Bradshaw | Head of Technical Operations | -- | -- | -- |
| Luis Sanay | Head of Investor Relations | -- | -- | -- |
| Mr. Christian Ulrich | General Counsel & Corporate Secretary | -- | -- | -- |
| Ms. Tricia Glover | Chief Compliance Officer | -- | -- | -- |
| Ms. Audrey Murphy SPHR | Vice Presidet of Human Resources | -- | -- | -- |
Harmony Biosciences Holdings, Inc.
630 West Germantown Pike
Suite 215
Plymouth Meeting, PA 19462
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 246
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Corporate Governance
Harmony Biosciences Holdings, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 8; Board: 10; Shareholder Rights: 8; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Apr 11, 2024DEFA14A: Proxy StatementsSee Full Filing
- Feb 28, 202410-K/A: Periodic Financial ReportsSee Full Filing
- Feb 22, 202410-K: Periodic Financial ReportsSee Full Filing
- Jan 24, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing
- Jan 08, 20248-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
Apr 30, 2024 - May 06, 2024
Harmony Biosciences Holdings, Inc. Earnings Call
Related Tickers
UTHR United Therapeutics Corporation
235.95
-0.44%
MORF Morphic Holding, Inc.
27.98
+1.05%
NAMS NewAmsterdam Pharma Company N.V.
21.44
-1.65%
VYGR Voyager Therapeutics, Inc.
7.42
-1.98%
PBYI Puma Biotechnology, Inc.
4.8800
+1.04%
PTCT PTC Therapeutics, Inc.
25.49
+1.11%
LGND Ligand Pharmaceuticals Incorporated
70.37
-0.89%
XENE Xenon Pharmaceuticals Inc.
40.10
+1.52%
PLRX Pliant Therapeutics, Inc.
11.88
-0.17%
PHVS Pharvaris N.V.
22.77
+7.15%